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Abstract
Background: Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment
consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide
(TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated
the feasibility and treatment response of subvolume boosting to a PET-defined tumor part.
Method: F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI.
A dose of 20 Gy (5 × 5 mm2) was delivered to the target volume delineated based on T1w MRI for three
treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy (1 × 1 mm2)
delivered to the region either with maximum [18F]FET or [18F]FAZA PET tracer uptake, respectively. All therapy groups
received intraperitoneal (IP) injections of TMZ. Finally, a control group received no RT and only control IP injections. The
average, minimum and maximum dose, as well as the D90-, D50- and D2- values were calculated for nine rats
using both RT plans. To evaluate response to therapy, follow-up tumor volumes were delineated based on
T1w MRI.
Results: When comparing the dose volume histograms, a significant difference was found exclusively between the
D2-values. A significant difference in tumor growth was only found between active therapy and sham therapy
respectively, while no significant differences were found when comparing the three treatment groups.
Conclusion: In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma
in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for
dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory.
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Background
Glioblastoma (GB) is the most common primary malig-
nant brain tumor. It has been given the highest grade of
WHO classification of glioma (WHO grade IV) and is a
highly invasive solid tumor [1–3]. Histologically, GBs are
characterized by increased vascularity, nuclear atypia,
necrosis and increased mitotic activity. Tumor cell infil-
tration deep into the surrounding brain parenchyma
renders a complete surgical resection elusive leading in-
evitably to tumor recurrence in most cases [4, 5].
Several factors such as lesion size, location and growth
rate determine the clinical presentation of patients with
GB. Headache, seizures, personality changes and focal
neurological deficits are common symptoms of GB [1].
The clinical course of GB is rapidly progressive, with a
mean survival time between six to fourteen months.
Standard medical treatment consists preferably, and if
possible, of a maximal safe surgical resection. Subse-
quently radiotherapy (RT; 60 Gy in 30 fractions) and
concomitant chemotherapy with temozolomide (TMZ;
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75mg/m2 during six weeks) followed by adjuvant
chemotherapy with TMZ (150–200 mg/m2 × 5 days, dur-
ing 6 cycli of 28 days) are administered. Even with this
treatment strategy, patients with GB typically develop
fast post-operative progression resulting in fatal outcome
for the majority of them [1, 6].
To improve this poor survival rate, new treatments are
crucial. RT is an essential part of (postoperative) GB treat-
ment, as has been demonstrated in the past [7]. RT plan-
ning is currently based on contrast-enhanced computed
tomography (CT) and magnetic resonance imaging (MRI).
The International Commission on Radiation Units and
Measurements Report No. 50 (ICRU-50) proposed to de-
lineate three different target volumes based on diagnostic
imaging (Fig. 1) [8]. The gross tumor volume (GTV)
reflects the macroscopical tumor volume as assessed by
contrast-enhanced anatomical imaging. To include the
microscopic infiltration into the adjacent healthy brain
tissue, an extra margin is proposed being the clinical tar-
get volume (CTV). Finally, the planning target volume
(PTV) also accounts for interfractional and intrafractional
variations [9, 10].
In 2000, Ling et al. (10) introduced the biological target
volume (BTV). The BTV is based on the concept that ir-
radiation of the tumor region with an adapted dose based
on proliferative activity, could result in a better outcome.
To include BTV in the treatment protocol, a non-uniform
dose can be delivered to the target volume based on func-
tional imaging (i.e. dose painting) [11, 12]. Hence, add-
itional biological information from positron emission
tomography (PET) may have added value for defining this
RT target tumor volume [12, 13]. The use of BTV in a
(pre)clinical set up has been evaluated by Trani et al. (11)
where they demonstrate the technical feasibility of preclin-
ical dose painting strategies. However, more preclinical
studies that confirm these results, or are aimed at testing
similar biological hypotheses, are needed [12, 14].
O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) and 1-α-
D-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimi-
dazole ([18F]FAZA) were selected as tracers for PET-guided
RT. Uptake of the amino acid PET tracer, [18F]FET, corre-
lates with tumor cell density and proliferation and is there-
fore able to identify tumor regions susceptible to relapse
[15, 16]. Uptake of the hypoxia tracer, [18F]FAZA, is corre-
lated with tumor hypoxia, which can cause radioresistance
[16, 17]. As such, a higher radiation dose targeting those
specific regions might be beneficial [18].
Rat models have remained the mainstay of neuro-on-
cology research for over 30 years. The C6 glioma has
been used extensively for a variety of studies, however, it
has the potential to evoke an immune response and it is
not syngeneic to any inbred strain [19, 20]. The 9 L glio-
sarcoma has been widely used but can be immunogenic
in syngeneic hosts. The U251 xenograft model shows
histological characteristics of human GB and displays
genetic similarities to human GB but is criticized for an
inadequate tumor-host immune response [21]. The U87
GB model displays key dissimilarities to human GB at
the histopathological level. Unlike GB, U87 tumors show
a non-diffusely infiltrative growth pattern, with more
homogeneous and leaky vessels [21, 22]. It is also worth
mentioning that patient-derived glioblastoma models
would necessitate the use of nude rats, which are much
more expensive. Taking these models in consideration,
the F98 GB model was selected for this preclinical study
based on the presence of all the necessary histologic
Fig. 1 Schematic illustration of the different volumes as defined in ICRU Report 50. Gross tumor volume (GTV) denotes the demonstrated tumor.
Clinical target volume (CTV) takes the tumor infiltration outside the GTV into account. The planning target volume (PTV) consists of the CTV and a
margin to account for the interfractional and intrafractional variations [10]. Reproduced with permission of the International Commission on
Radiation Units and Measurements, https://ICRU.org
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characteristics, the costs and the extensive experience of
our research group with this model [23–26]. Recently, in
2017 Bolcaen et al. optimized a protocol for PET- and
MRI-guided irradiation of a GB rat model using a
micro-irradiator [23]. Using this approach, it is our goal
to conduct a proof of concept for the application of
PET-defined subvolume boosting using two different




The study was approved by the Ghent University ethics
committee for animal experiments (ECD 12/28-A2). All
animals were kept and handled according to the Euro-
pean guidelines (2010/63/EU) and housed under envir-
onmentally controlled conditions (12 h normal light/
dark cycles, 20 °C – 24 °C and 40–70% relative humidity)
with food and water ad libitum.
The GB F98 rat model was developed as described by
Bolcaen et al. [26]. In summary, F98 rat GB cells were
cultured as monolayers for three weeks. 54 Female
Fisher F344 rats (Charles River®) were anesthetized with
ketamine/xylazine (i.p., 4/3; 0.13 mL/100 g), and immo-
bilized using a stereotactic frame (Model 902 Dual Small
Animal Stereotaxic frame, Kopf®). After shaving, the
head was swabbed with betadine and the skull was ex-
posed through a longitudinal 1 cm scalp incision. Using
a diamond drill (Dremel®), a 1 mm hole was made
through the skull (2.5 mm lateral to the bregma in the
right frontal hemisphere). A stereotactically guided 1 mL
insulin needle was inserted at a depth of 3 mm and 5 μL
of cell suspension containing 20,000 F98 cells in
phosphate-buffered saline was delivered. This cell sus-
pension was injected using a microsyringe pumpcontrol-
ler (Micro 4TM, World Precision Instruments, Sarasota,
USA) over a 2-min period. The syringe was slowly with-
drawn 1min post inoculation and the incision was
closed with bone wax (Aesculap AG®) and sutured.
MRI
Eight days post inoculation small animal MRI was per-
formed on a 7 T system (PharmaScan 70/16, Bruker,
Ettlingen, Germany) to confirm tumor growth. Rats were
anesthetized with 2% isoflurane mixed with oxygen ad-
ministered at a flow rate of 0.3 L/min. To enable the in-
jection of a gadolinium containing contrast agent
(Dotarem®, Guerbet, 2 mmol/kg), a 30-Gauge needle
connected to a 60 cm long PE tube was placed intraven-
ously in the lateral tail vein. A rat brain surface coil
(Rapid Biomedical, Rimpar®, Germany) was applied
around the head of the animal followed by positioning
of the bed in a 72mm whole body transmitter coil
(Rapid Biomedical, Rimpar®, Germany). A T2-weighted
scan (T2w SE RARE, TR/TE 3661/37.1 ms, 109 μm iso-
tropic in plane resolution, 4 averages, TA 9′45″) was
performed to localize the tumor. If tumor was visually
confirmed, a 5 min T1w scan was obtained after injec-
tion of the gadolinium containing contrast agent.
PET imaging
PET images were acquired on a small animal PET scanner
(FLEX Triumph II, TriFoil Imaging®, Northridge, CA,
USA). A 30min PET scan was obtained with [18F]FET or
[18F]FAZA (±37MBq; 30min or 2 h post-injection, re-
spectively). This time frame allowed to acquire the MRI
scans during tracer uptake. Reconstruction of the PET
scans was done by a 2D Maximum Likelihood Expectation
Maximization (MLEM) algorithm (LabPET Version
1.12.1, TriFoil Imaging, Northridge, CA, USA) applying 50
iterations and a using voxel size of 0.5 × 0.5 × 1.157mm3
into 200 × 200 × 64 matrix.
Treatment groups
Different therapy groups were defined based on the
definition of the target volumes for brain tumor ir-
radiation. For the MRI based RT group (n = 5), the
isocenter was placed in the middle of the contrast
enhancement on T1-weighted (T1w) MRI (Fig. 2).
The [18F]FET-PET based RT (n = 6) and [18F]FAZA-
PET based RT (n = 4) groups received an additional
radiation boost of 5 Gy delivered to the region either
with maximum [18F]FET or [18F]FAZA PET tracer
uptake, respectively.
All therapy groups received concomitant treatment
consisting of intraperitoneal (IP) injections of TMZ on
five consecutive days, starting on the same day as the
RT [27, 28]. Therefore, 29 mg/kg TMZ (Sigma-Aldrich®)
was dissolved in saline with 25% dimethylsulfoxide.
Finally, a control group (n = 5) received no RT and only
control IP injections with an equal amount of dimethyl-
sulfoxide and saline on five consecutive days.
Animals with MRI-confirmed GB-tumor were ran-
domly assigned to the abovementioned groups.
Radiation treatment
Radiotherapy treatment was performed using a small
animal radiation research platform (SARRP, Xstrahl®,
Surrey, UK). MRI-based RT in the F98 GB rat model
was already optimized by our research group [23, 29].
A gadolinium-based contrast agent was intravenously
injected, followed by fixation of the animal on a mul-
timodality bed. Two water filled capillaries were used as
markers and were placed on the right side and in the mid-
dle of the rat head. After acquiring contrast-enhanced
T1w spin-echo scans, the rat was transported to the
four-axis robotic positioning table of the SARRP, while
fixed on the multimodality bed. A treatment planning CT
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was obtained using the following acquisition parameters:
50 kV tube voltage, 600 μA tube current, 360 projection
acquired over 360 degrees using a 1mm Al-filter, resulting
in a total acquisition time of 1 min. The acquired projec-
tion data were reconstructed using an isotropic voxel size
of 0.2 mm. After importing the planning CT into the
treatment planning software (Muriplan, Version 2.0.6,
Xstrahl®, UK), manual segmentation was performed to dis-
tinguish air, soft tissue and bone. Co-registration with the
MRI was done manually using the capillary markers and
the skull. Based on the contrast-enhanced T1w MRI scan
the isocenter of the radiation bundle was set in the middle
of the tumor region. A single dose of 20Gy was delivered
by applying three non-coplanar arcs (120°) using a 5 × 5
mm2 collimator to include minor position changes of the
rat head during execution of the treatment.
For the PET/MRI-based RT planning, co-registration
of PET and planning CT was performed using PMOD
(version 3.31, PMOD technologies, Ltd). First, the con-
trast-enhanced T1w MRI scan was co-registered with the
planning CT as described above. Then, the PET image
was co-registered with the planning CT. Finally, the co-
ordinates of the isocenters based on 1) contrast en-
hancement on the T1w MRI scan and 2) based on
maximum tracer uptake in the PET image were
determined in PMOD and transferred to Muriplan.
The isocenter indicated on the MRI scan received a
single dose of 20 Gy using a 5 × 5 mm2 collimator as
described above, while the isocenter based on max-
imum PET tracer uptake received an additional 5 Gy
boost using a 1 × 1 mm2 collimator. The method-
ology has been described in detail in a recently pub-
lished Jove Movie [23].
Chemotherapy
Concomitant chemotherapy was given on five consecu-
tive days starting on the same day as the RT. Therefore,
IP injections of 29 mg/kg TMZ (Sigma-Aldrich®) dis-
solved in saline with 25% dimethylsulfoxide were per-
formed. The control group received IP injections with
an equal amount of dimethylsulfoxide and saline on five
consecutive days [27, 28].
Histological characterization
At the end of the experiment or when the humane end-
points were reached (> 20% weight loss, tumor vol-
ume > 40% of total brain volume based on MRI or signs
of ataxia) rats were euthanized by an IV injection of
pentobarbital (120 mg/kg). From five animals the brain
was isolated, dissected, immersed in 4% paraformalde-
hyde for 24 h and embedded in paraffin. Then, the
brain was partly sectioned into 5 μm slices and stained
with hematoxylin and eosin (HE) in order to histologi-
cally characterize the tumor.
Comparison of [18F]FET and [18F]FAZA PET
The uptake of both tracers was studied in the same F98
GB rat (n = 3). Additionally, the pre-RT PET scans of
the [18F]FET-PET based RT (n = 6) and [18F]FAZA-PET
(n = 4) based RT groups were analyzed. Using PMOD,
rigid body transformations were applied to co-register
the PET and MRI scans. Volumes of interest (VOI) were
drawn manually and included the contrast-enhanced re-
gion on the T1w MRI scans. Cubic VOIs of 2 × 2 × 2
mm3 located in the contralateral region were used as a
reference (background region). Tracer uptake in the VOI
Fig. 2 Overview of the four research groups. A dose of 20 Gy was delivered to the target volume delineated based on T1w MRI for three
treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy delivered to the region either with maximum
[18F]FET or [18F]FAZA PET tracer uptake, respectively. All therapy groups received intraperitoneal (IP) injections of TMZ. Finally, a control group
received no RT and only control IP injections
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at each time frame was converted to a standardized up-
take value (SUV) according to the following formula:
SUV = (Radioactivity in VOI expressed in Bq/ml /
injected activity in Bq) x body weight in g.
Injected activity was corrected for radioactive decay
and residual activity in the syringe. Standardized uptake
values (SUVmean and SUVmax) and tumor-to-background
ratios (TBRmean and TBRmax) were calculated.
Dose volume histograms
To compare the dose of MRI-based RT with PET/MRI--
based sub-volume boosting, dose volume histograms
(DVH) were analyzed. Using Muriplan, the DVHs were
determined within the overlapping volume of the three
rotating 5 × 5mm2 bundles using Muriplan. The average,
maximum and minimum dose, as well as the D2-, D50-,
and D90-values, were determined and compared between
different RT treatment plans. Dx stands for the dose that
x % of the tissue volume received.
Assessment of therapy response
Tumor growth was evaluated by obtaining sequential
MRI scans 2, 5, 9, 12, 14, and 16 days after initiating the
treatment. Tumor volumes were measured by manually
outlining the tumor on individual slices of contrast-en-
hanced T1w images using PMOD.
Statistical analysis
Statistical analyses were done using SPSS software (SPSS
Statistics 23 software). If applicable, a Mann-Whitney U
test was applied. A probability value of p < 0.05 was con-
sidered statistically significant. Values are presented as
mean ± SD.
Results
F98 GB rat model
HE staining of rat 7 (Fig. 3) shows typical characteristics
of GB. On the overview picture (left) tumor necrosis
(region A), tumor (region B) with strong infiltration (re-
gion C) of the surrounding healthy brain tissue (region
D) is clearly visible. Increased cellularity, more nuclear
pleomorphism and atypia, increased proliferation (region
E), microvascular hyperplasia (region F) and necrosis
(region G) is displayed on the detailed section.
Comparison [18F]FET and [18F]FAZA PET
The uptake of both tracers is increased in the tumor region
compared to the surrounding healthy brain tissue (Fig. 4).
The SUVmean, SUVmax, TBRmean and TBRmax - values of
the [18F]FET and [18F]FAZA pre-RT PET scans were com-
pared using the Mann-Whitney U test (Table 1). The aver-
age SUVmean in the tumor was significantly higher for
[18F]FET (0.80 ± 0.16) compared to [18F]FAZA (0.10 ± 0.05)
(p = 0.024). A significant difference was also found for the
average SUVmax as [
18F]FET (1.21 ± 0.23) was significantly
higher compared to [18F]FAZA (0.16 ± 0.07) (p = 0.024).
The average SUVmean, SUVmax values in healthy brain tis-
sue were also significantly higher for [18F]FET (SUVmean
0.45 ± 0.08; SUVmax 0.60 ± 0.09) compared to [
18F]FAZA
(SUVmean 0.07 ± 0.03; SUVmax 0.09 ± 0.04) (p = 0.024). Like-
wise, the average TBRmean of [
18F]FET (1.79 ± 0.33) was sig-
nificantly different compared to [18F]FAZA (1.35 ± 0.14)
(p = 0.048). However, between the average TBRmax values
no significantly difference was found ([18F]FET: 2.72 ± 0.53;
[18F]FAZA: 2.23 ± 0.13).
Radiotherapy
MRI-based RT and PET/MRI-based sub-volume boost-
ing using [18F]FET and [18F]FAZA were successfully per-
formed. However, the MRI guided irradiation with PET
sub-volume boosting is very time consuming. A timeline
of a PET based RT experiment can be found in Fig. 5.
The imaging and RT protocol can take up to 4 h.
Figure 6 shows a planning CT (upper row), a contrast-
enhanced T1w MRI (middle row) and a [18F]FET-PET
image (bottom row) that were co-registered manually
Fig. 3 HE staining of rat 7 (MRI based RT group, 32 days post inoculation) confirms the presence of GB. On the overview picture (left) central
tumor necrosis (a), tumor (b), infiltration (c) of the surrounding healthy brain tissue (d) can be seen. The detailed section shows increased
cellularity, more nuclear pleomorphism and atypia, increased proliferation (e), microvascular hyperplasia (f) and necrosis (g)
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into PMOD to determine the isocenters for RT planning.
Figure 7 shows the dose distribution using six non-co-
planar arcs as described by Bolcaen et al. [23].
Dose volume histograms
The average, minimum and maximum dose, as well as
the D90-, D50- and D2- values, were calculated for MRI-
and PET/MRI-based RT plans (See Additional file 1:
Supplementary data 1 and 2). The Mann-Whitney U test
revealed that the average (1845 ± 36 cGy for MRI vs 1872 ±
36 cGy for PET), maximum (2405 ± 245 cGy for MRI vs
2560 ± 127 cGy for MRI/PET) and minimum (625 ± 146
cGy for MRI vs 654 ± 133 cGy for PET/MRI) doses were
not significantly different (p = 0.113; p = 0.063; p = 0.489 re-
spectively). The D90- (1502 ± 78 cGy for MRI vs 1513 ± 89
cGy for PET/MRI) and D50-values (1922 ± 34 cGy MRI vs
1933 ± 41 cGy MRI/PET) were also not significantly differ-
ent (p = 0.666 and p = 0.0.546). However, the D2-values
(2122 ± 44 cGy MRI vs 2213 ± 54 cGy PET/MRI) were sig-
nificantly different (p = 0,002). The difference in DVH was
minimal. The graph shows a slight shift to the right for the
DVH based on the RT with PET/MRI based sub-volume
boosting (Fig. 8). A representable DVH for the 5 Gy boost
can be found in Additional file 1: Supplementary data 3.
Response to therapy
To evaluate the response to therapy, 180 follow-up MRI
scans were obtained until 36 days after tumor confirm-
ation (Additional file 1: Supplementary data 4 and 5).
Tumor volumes were delineated based on the contrast-
enhancing tumor volume on T1w MRI. The absolute
tumor volumes were normalized to the volume before
starting RT treatment. The influence of therapy on the
normalized tumor volumes is shown in Fig. 9. Tumor
volumes were compared at different time points in all
groups with the Mann-Whitney U test. Tumor volume
on day 2 is significantly higher in the control group
compared to the MRI based RT group (p = 0.008), while
no significant difference was found compared to the
PET based RT-groups ([18F]FET PET p = 0.429 and
[18F]FAZA PET p = 0.413). On day 5 and 9 post ther-
apy, the tumor volume was significantly lower for all
three treatment groups compared to the control group
(day 5: MRI p = 0.008, [18F]FET p = 0.045, [18F]FAZA
Fig. 4 Comparison of the [18F]FET and [18F]FAZA uptake on two
consecutive days in the same rat (not a rat included in the
treatment groups, 13 days post inoculation). Upper row represents
PET scans. Bottom row shows the contrast-enhanced T1wMRI scans.
The full white line represents rat brain
Table 1 SUV and TBR-values of [18F]FET and [18F]FAZA pre-RT-PET scans
Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Average SD
[18F]FET SUVmean 0.60 0.65 1.04 0.91 0.83 0.80 0.80 0.16
SUVmax 0.95 1.00 1.57 1.40 1.16 1.20 1.21 0.23
SUVmean normal tissue 0.37 0.37 0.46 0.43 0.59 0.49 0.45 0.08
SUVmax normal tissue 0.51 0.65 0.56 0.53 0.75 0.62 0.60 0.09
TBRmean 1.60 1.73 2.24 2.13 1.40 1.64 1.79 0.33
TBRmax 2.56 2.68 3.38 3.26 1.97 2.46 2.72 0.53
Rat 7 Rat 8 Rat 9 Rat 10
[18F]FAZA SUVmean 0.13 0.12 0.04 0.07 0.10 0.05
SUVmax 0.21 0.18 0.08 0.12 0.16 0.07
SUVmean normal tissue 0.10 0.08 0.03 0.05 0.07 0.04
SUVmax normal tissue 0.23 0.11 0.05 0.08 0.13 0.09
TBRmean 1.32 1.50 1.23 1.39 1.35 0.14
TBRmax 2.11 2.36 2.23 2.32 2.23 0.13
Verhoeven et al. Radiation Oncology           (2019) 14:89 Page 6 of 11
p = 0.016; day 9: MRI p = 0,036, [18F]FET p = 0,024,
[18F]FAZA p = 0,057). On day 12, a significant differ-
ence was only found between the control group and
the [18F]FET PET group (p = 0.046). Compared to the
[18F]FAZA group, the difference is borderline not sig-
nificant (p = 0.064). After day 14 no significant differ-
ences could be found between the different therapy
groups.
Discussion
Given the poor survival of GB patients, there is an urgent
need for improving current and developing new treatment
methods. Multiple therapies have been proposed at the
time of GB recurrence including cytotoxic chemotherapy,
immunotherapy, angiogenesis inhibitors,… [30]. Unfortu-
nately, none of these therapies turned out to be a big
breakthrough [31]. Therefore, more research is being done
in optimizing the currently used radiation therapy to
provide the best possible outcome [18]. Although a
dose-response relationship in GB is well known, escalation
studies giving a higher dose to the entire tumor have not
been successful [32]. PET-guided RT targeting the most
metabolically active or radioresistant tumor region with
RT might improve local tumor control without comprom-
ising normal surrounding brain and possibly lead to a bet-
ter survival in GB patients. However, only limited studies
have been performed using PET guided RT in GB rats.
Menichetti et al. demonstrated the usefulness of [18F]FET-
PET guided boron neutron capture therapy in F98 rats
[33]. However, several groups have been incorporating op-
tical molecular imaging techniques such as biolumines-
cence and fluorescence imaging, to guide RT successfully
[34–38]. Unfortunately, optical imaging has limited spatial
resolution due to tissue absorption and scatter of visible
light and background artifacts need to be taken into ac-
count caused by auto-fluorescence [39]. Most importantly,
bioluminescent imaging cannot be easily translated to the
clinic as it requires genetic manipulation of tumor cells.
As such, the implementation of PET for RT planning
looks promising [40].
In our F98 GB rat model, the TBRmean value of [
18F]FET
was significantly higher compared to [18F]FAZA, suggest-
ing that distinction between tumor and healthy brain tis-
sue was more evident on the [18F]FET PET scan.
Unfortunately, there are only few studies available that
describe the uptake of [18F]FAZA in GB patients or in a
GB rat model. In order to characterize the biological fea-
tures of the F98 GB model, Belloli et al. [41] studied the
uptake of [18F]FDG and [18F]FAZA. Contrary to our
study, the [18F]FAZA uptake in the study by Belloli et al.
was centrally located and showed a TBR value of 2.2 ± 0.4,
whereas in our study a lower TBRmean for [
18F]FAZA, i.e.
1.35 ± 0.14, was observed. In agreement with the study by
Belloli et al., visual analysis of the PET scans with different
tracers showed a more centrally located [18F]FAZA uptake
in the tumor in comparison to [18F]FET uptake. The latter
is in agreement with the knowledge that the most hypoxic
tumor regions are centrally located whereas viable tumor
cells, surrounding tumor necrosis are situated in the
Fig. 5 Timeline of a PET based RT experiment. The entire radiation process can take up to 4 h
Fig. 6 Planning CT (upper row), contrast-enhanced T1w MRI (middle
row) and [18F]FET PET image. To perform PET-based sub-volume
boosting, these three imaging modalities were co-registered
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periphery of the tumor. As described by several research
groups both [18F]FET and [18F]FAZA are suitable PET
tracers for the purpose of sub-volume boosting [41, 42].
In agreement with the histological findings, GB is
characterized by central tumor necrosis with a viable
and rapidly infiltrating tumor rim whereas hypoxic
regions are observed in the middle of the tumor and re-
gions with elevated amino acid transport are detected at
the border of the tumor [19].
RT was given using three non-coplanar arcs in order to
limit the dose delivered to healthy brain tissue [29, 43].
However, some shortcomings of the SARRP system should
be considered. The used collimators are rigid (square aper-
ture of 12–52mm2) and therefore not conformed to the
shape of the tumor. This might possibly be solved by devel-
oping a multi-leaf collimator as is being used in the clinic.
In addition, this would also allow the use of intensity-
modulated radiotherapy (IMRT), which is a common
practice in the clinic. Dose painting by numbers, impos-
sible without IMRT, was not possible due to unavailability
of software needed for performing the calculations. Due to
these restrictions, we opted for a set up with sub-volume
boosting using a 1 × 1mm2 collimator to deliver an add-
itional dose of 5 Gy to the tumor region corresponding
with the highest PET signal.
By means of DVHs the influence of the extra 5 Gy on
the total tumor dose was estimated for the groups re-
ceiving the PET based subvolume boost irradiation. Only
the dose that was delivered to 2% of the tumor volume
(which corresponds with the maximum dose) was sig-
nificantly different. This can be explained by higher dose
values in the groups with PET sub-volume boosting in
Fig. 7 Representation of RT treatment plan using six non-coplanar arcs. One isocenter was based on the center of the contrast enhanced using a T1w
MRI scan, while another isocenter was based on maximum PET tracer uptake. These two isocenters are indicated in green or red, respectively
Fig. 8 Indication of the overlapping volume of the three rotating bundles (green, a). Dose volume histogram with isocenter based on the center
of the gadolinium containing contrast uptake on the T1wMR image (b). Dose volume histogram with the second isocenter based on maximum
tracer uptake as shown on the PET scan (c)
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comparison to dose values calculated based on the MRI
based irradiation. The results illustrate that there is no
significant difference regarding the delivered dose lo-
cated at the tumor volume between the three therapy
groups. This means that the PET sub-volume boosting
does not result in a higher radiation burden for the adja-
cent brain. It should be noted that using a 1 × 1mm2 colli-
mator to perform the boosting results in a very limited
volume receiving the additional 5 Gy. If a larger target vol-
ume would be used, the DVHs would differ considerably.
Tumor volumes at different timepoints were compared
with the Mann-Whitney U test. Soon after initiation of
therapy, the first effect of treatment was visible showing a
significant difference in tumor volumes from day 5 until
day 12 between the treated and control groups. However,
no significant differences were observed between the MRI
based and [18F]FET- vs. [18F]FAZA-PET based RT groups.
Tumor growth in the MRI based RT group corresponded
to our previously published results [29], where GB was
treated with RT and TMZ in the F98 rat model. The
growth of the tumor remained stable until day 9 after
therapy, while a continuous increase in tumor volume was
observed in the control group.
Three important limitations of this study include the
resolution of the PET scanner (1.2 mm) and the limited
number of rats that completed the study. A more accur-
ate delineation of the BTV might be possible by using a
small animal PET scanner with better spatial resolution.
Secondly, taking into account the humane endpoints,
several animals had to be euthanized early due to clinical
deterioration as result of large tumors as previously de-
scribed by Schültke et al. [44]. This issue will influence
the average values significantly. To prolong the follow-up
period of the rats, inoculation of the tumor in the thigh
could be an alternative [14]. However, subcutaneous gli-
oma models lack the specific CNS microenvironment that
has an essential role in glioma biology and progression
[45]. Finally, the implementation of preclinical PET guided
irradiation is very time consuming. A timeline is shown in
Fig. 5. Using our GB rat model, we are obliged to perform
the imaging and irradiation subsequently, while the rat is
continuously fixed to a multimodality bed with multimod-
ality markers fixed to the head. This is necessary to be able
to perform exact manual image fusion using the radiation
planning software or PMOD, as automatic image fusion is
still not reliable in small animals. Patients don’t have their
imaging and irradiation subsequently as image fusion soft-
ware is perfectly able to fuse MRI/CT/PET images. Fur-
thermore, manual segmentation of the CT image is
necessary for dose calculation, while this is not the case in
patients. Also, the preclinical RT planning has to be per-
formed immediately after the CT to exclude a change of
the rats position and to limit the total anesthesia time. In
patients, the radiation therapist starts to design a RT plan
after receiving the multi-modilty images and subsequently
the first treatment of the patient can be initiated. As such,
the timeline of the imaging and RT planning of a patient is
covered over days while preclinically all these steps have to
be performed in a few hours during anesthesia of the rat.
Taking the limitations into account, our data demon-
strates the feasibility of dose targeting in a F98 rat GB
model using MR, [18F]FET- and [18F]FAZA-PET imaging.
However, technical advances are needed to apply a
non-uniform dose to a target region more accurately.
Fig. 9 Graphical representation of the median (+SD) change of the tumor volume by day
Verhoeven et al. Radiation Oncology           (2019) 14:89 Page 9 of 11
Conclusions
In this study, we showed the feasibility of PET guided
subvolume boosting in a rat GB model. Comparing the
effect of therapy applying MRI-based RT versus PET-based
sub-volume boosting, we concluded that only a significant
difference in tumor growth was found between active ther-
apy and sham therapy respectively, while no significant dif-
ferences were found when comparing the three treatment
groups. Improvements for dose targeting in rodents are
mandatory to apply a non-uniform dose to the more resist-
ant regions of the tumor which might then be beneficial in
terms of local tumor control. The latter combined with ne
targeted drugs for GB treatment is, in our opinion, the
most promising strategy.
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